PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, IGC Pharma's PE Ratio without NRI is 0.00. IGC Pharma's 5-Year EBITDA growth rate is 11.30%. Therefore, IGC Pharma's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for IGC Pharma's PEG Ratio or its related term are showing as below:
IGC's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.92 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
IGC Pharma (AMEX:IGC) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
IGC Pharma PEG Ratio Related Terms
IGC Pharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for IGC Pharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where IGC Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
IGC Pharma (IGC) has a PEG Ratio of 0.00 as of Jun. 28, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #999999 out of 95 companies in the Biotechnology industry.
Is IGC Pharma's PEG Ratio too high?
IGC Pharma's current PEG Ratio is 0.00. Based on the distribution chart, IGC Pharma ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's PEG Ratio compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #999999 out of 95 companies for PEG Ratio. This places IGC Pharma in the lower half of its industry. The industry median PEG Ratio is 1.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.92, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 9.6% above its estimated fair value. The current PEG Ratio is 0.00. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For IGC Pharma (IGC), the current PEG Ratio is 0.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.26 is trading 9.6% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Fairly Valued.
Key valuation signals for IGC:
PEG Ratio: 0.00
GF Value™: $0.24 vs. price of $0.26 (9.6% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
